Skip to content
value.today

Acro Biomedical Co., Ltd.

ACBM
$240 Mlast known market cap, Dec 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2025
Net income
$-0 M
SEC filing
Employees
—

Acro Biomedical Co., Ltd. in brief

Acro Biomedical Co., Ltd. is a listed company in the Biotechnology industry, based in Fishers, Indiana, USA. It was founded in 2014. Its last known market value was $240 M (December 2022); there is no current figure.

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Acro Biomedical Co., Ltd.

Since January 30, 2017, following a change of control, our business has been the development and marketing nutritional products that promote wellness and a healthy lifestyle. Our revenue to date has resulted from the purchase of products from three suppliers in the Republic of China (Taiwan), one of which accounted for all of our purchases in the year ended December 31, 2022. We have not generated any revenue in the second and third quarters of 2022 and subsequent to December 31, 2022 through the date of this annual report, and we did not purchase any inventory since the second quarter of 2022.

From the company's annual report filed with the US SEC: read the report

Acro Biomedical Co., Ltd. timeline

4 events, 2014–2021
  1. 2014
  2. 🏁
    · approximate
    Founded
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2017
  5. ✎
    Renamed Acro Biomedical Co., Ltd.
    Formerly Killer Waves Hawaii, Inc.
  6. 2021
  7. 💰
    Record revenue of $1 million
    FY2021, the highest of the 4 years on record.

Events of Acro Biomedical Co., Ltd. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$70 M$141 M$211 M$282 M202020212022

World rank over time

▼ down 587 places since 2020
2020-01-01: #16475#16,47520202021-01-01: #16927#16,92720212022-01-07: #17558#17,55820222022-12-25: #17062#17,0622022

Rank in USA: #3,333 (Jan 2020) · #3,487 (Jan 2021) · #3,602 (Jan 2022) · #3,486 (Dec 2022)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
—
Liabilities / assets
4000.0%
Revenue growth
-45.0%
R&D / revenue
1527.3%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Sep 2018: revenue $8M, net income $0M$8MFY18Fiscal year ending Dec 2019: revenue $0M, net income $-0M$0MFY19Fiscal year ending Dec 2020: revenue $1M, net income $-0M$1MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-8M$1MFY21Fiscal year ending Dec 2022: revenue $1M, net income $-16M$1MFY22Fiscal year ending Dec 2023: revenue —, net income $-9M—FY23Fiscal year ending Dec 2024: revenue —, net income $-0M—FY24Fiscal year ending Dec 2025: revenue —, net income $-0M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-0M$-0M—
Dec 2024——$-0M$-0M—
Dec 2023——$-9M$-9M—
Dec 2022$1M-45.0%$-16M$-16M-2404.5%
Dec 2021$1M+73.9%$-8M$-8M-641.7%
Dec 2020$1M+263.2%$-0M$-0M-17.4%
Dec 2019$0M-97.6%$-0M$-0M-194.7%
Sep 2018$8M—$1M$0M5.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-0M——$0.00—
Dec 2024$-0M——$0.00—
Dec 2023$-0M——$-0.15—
Dec 2022$-0M——$-0.26—
Dec 2021$0M————
Dec 2020$-0M——$0.00—
Dec 2019$-0M——$-0.01—
Sep 2018$-0M——$0.01—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-0M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-0M—Dec ’24Three months to Mar 2025: revenue —, net income $-0M—Mar ’25Three months to Jun 2025: revenue —, net income $-0M—Jun ’25Three months to Sep 2025: revenue —, net income $-0M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $0M—Dec ’25Three months to Mar 2026: revenue —, net income $-0M—Mar ’26Three months to Jun 2026: revenue —, net income $-0M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Acro Biomedical Co., Ltd. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-0 M
Net income
$-0 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$0 M
Total liabilities
$0 M
Total equity
$-0 M

As of December-2025

Markets and events: Acro Biomedical Co., Ltd.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Stock splits: 2-for-1 split

Acro Biomedical Co., Ltd. scorecard#

Passes 2 of the 7 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
  • Growth1 of 2
  • Profitability0 of 2
  • Financial health0 of 2
  • Shareholder returns1 of 1

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Acro Biomedical Co., Ltd.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Acro Biomedical Co., Ltd.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Sep 30, 2019FY 2018to Sep 30, 2018FY 2017to Sep 30, 2017FY 2016to Sep 30, 2016
Income statement
Revenue0006591,1986881,3548,015510—
Cost of revenue——05189385291,2197,181459—
Gross profit——014126015913583351—
Research and development—04,79510,0805,285—————
Selling, general and administrative154383,5185,9302,66829057731853r1.1
Operating expenses154388,80416,0107,9532905773185343
Operating income−154−38−8,804−15,870−7,694−130−442516−2.243
Interest expense and finance costs——3.21.7r0.91.1————
Other non-operating income (expense)53−4.3———−5.1−2.3−3.7——
Income before tax−101−42−8,808−15,871—−136−444512−2.2−43
Income tax00000−18−739200
Net income including minority interests−101−42−8,808r15,871——————
Net income attributable to shareholders−101−42−8,808−15,871−7,698−117−371420−2.2−43
Earnings per share, basic————-0.140.00-0.010.010.000.00
Earnings per share, diluted0.000.00-0.15-0.26—0.00-0.010.010.000.00
Shares, weighted average (diluted)60606060544848484747r
Balance sheet
Cash and cash equivalents4.10.50.45.995181.51.1372.5
Receivables——0639598—————
Inventory————09381,0601,147481—
Current assets145.11.66587069731,0691,4785482.5
Right-of-use (leased) assets02752265025————
Total assets1432586877619981,0691,4835482.5
Accounts payable56154154772625187.30.67.3
Current liabilities401327289201923121962413717
Lease liabilities (non-current)—0270260————
Total liabilities—3273152011173121962413717
Retained earnings−32,759−32,658−32,615−23,808−7,936−239−45325−94−92
Shareholders' equity−387−295−2574866446868741,242511−15
Total liabilities and equity1432586877619981,0691,4835482.5
Shares outstanding6060606060r4848484847r
Cash-flow statement
Share-based compensation—08,06115,7127,65103007.4——
Cash from operating activities−196−37−15−147299−19980−140−463−35
Shares issued————————500—
Cash from financing activities2003710.058−222217−7910549810
Change in cash—————170.3−3634−25
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K/A

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Jun 30, 2026

Events at Acro Biomedical Co., Ltd.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Auditor changedFiling

Auditor changed 3 · Directors and officers 3 · Bylaws or fiscal year changed 1 · Shareholder vote 1

Acro Biomedical Co., Ltd.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Auditor changed8-K
Directors and officers8-K
Auditor changed8-K
Directors and officersShareholder vote8-K
Bylaws or fiscal year changed8-K
Auditor changed8-K

As of Sep 2, 2026

How Acro Biomedical Co., Ltd. compares in Biotechnology

  • Revenue growth-45.0% · higher than 21% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Acro Biomedical Co., Ltd.🇺🇸$240 M——-45.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Dec 25, 2022 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Acro Biomedical Co., Ltd.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Acro Biomedical Co., Ltd.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Acro Biomedical Co., Ltd.? Suggest a correction